Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

19 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Time-lagged association between counseling and/or 12-Step attendance with subsequent opioid use in a secondary analysis from a randomized, clinical trial of medications for opioid use disorder.
Hefner K, Choo TH, Shmueli-Blumberg D, Pavlicova M, King J, Fishman M, Shulman M, Campbell A, Greiner M, Scodes J, Meyers-Ohki S, Novo P, Nunes E, Rotrosen J. Hefner K, et al. Among authors: shmueli blumberg d. Drug Alcohol Depend Rep. 2022 Dec;5:100100. doi: 10.1016/j.dadr.2022.100100. Epub 2022 Sep 29. Drug Alcohol Depend Rep. 2022. PMID: 36644220 Free PMC article.
Towards detecting cocaine use using smartwatches in the NIDA clinical trials network: Design, rationale, and methodology.
Holtyn AF, Bosworth E, Marsch LA, McLeman B, Meier A, Saunders EC, Ertin E, Ullah MA, Samiei SA, Hossain M, Kumar S, Preston KL, Vahabzadeh M, Shmueli-Blumberg D, Collins J, McCormack J, Ghitza UE. Holtyn AF, et al. Contemp Clin Trials Commun. 2019 Jun 4;15:100392. doi: 10.1016/j.conctc.2019.100392. eCollection 2019 Sep. Contemp Clin Trials Commun. 2019. PMID: 31245651 Free PMC article.
NIDA Clinical Trials Network CTN-0051, Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment (X:BOT): Study design and rationale.
Lee JD, Nunes EV, Mpa PN, Bailey GL, Brigham GS, Cohen AJ, Fishman M, Ling W, Lindblad R, Shmueli-Blumberg D, Stablein D, May J, Salazar D, Liu D, Rotrosen J. Lee JD, et al. Contemp Clin Trials. 2016 Sep;50:253-64. doi: 10.1016/j.cct.2016.08.004. Epub 2016 Aug 10. Contemp Clin Trials. 2016. PMID: 27521809 Free PMC article. Clinical Trial.
Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial.
Lee JD, Nunes EV Jr, Novo P, Bachrach K, Bailey GL, Bhatt S, Farkas S, Fishman M, Gauthier P, Hodgkins CC, King J, Lindblad R, Liu D, Matthews AG, May J, Peavy KM, Ross S, Salazar D, Schkolnik P, Shmueli-Blumberg D, Stablein D, Subramaniam G, Rotrosen J. Lee JD, et al. Lancet. 2018 Jan 27;391(10118):309-318. doi: 10.1016/S0140-6736(17)32812-X. Epub 2017 Nov 14. Lancet. 2018. PMID: 29150198 Free PMC article. Clinical Trial.
Core outcomes set for research on the treatment of opioid use disorder (COS-OUD): the National Institute on Drug Abuse Clinical Trials Network protocol for an e-Delphi consensus study.
Karnik NS, Campbell CI, Curtis ME, Fiellin DA, Ghitza U, Hefner K, Hser YI, McHugh RK, Murphy SM, McPherson SM, Moran L, Mooney LJ, Wu LT, Shmueli-Blumberg D, Shulman M, Schwartz RP, Stephens KA, Watkins KE, Marsden J. Karnik NS, et al. Among authors: shmueli blumberg d. Trials. 2021 Jan 28;22(1):102. doi: 10.1186/s13063-021-05051-9. Trials. 2021. PMID: 33509278 Free PMC article.
Moderation of buprenorphine therapy for cocaine dependence efficacy by variation of the Prodynorphin gene.
Nielsen DA, Walker R, Graham DP, Nielsen EM, Hamon SC, Hillhouse M, Shmueli-Blumberg D, Lawson WB, Shores-Wilson K, Settles-Reaves BD, Rotrosen J, Trivedi MH, Saxon AJ, Ling W, Kosten TR. Nielsen DA, et al. Among authors: shmueli blumberg d. Eur J Clin Pharmacol. 2022 Jun;78(6):965-973. doi: 10.1007/s00228-022-03302-5. Epub 2022 Feb 26. Eur J Clin Pharmacol. 2022. PMID: 35218405 Clinical Trial.
The opioid use disorder core outcomes set (OUD-COS) for treatment research: findings from a Delphi consensus study.
Karnik NS, Marsden J, McCluskey C, Boley RA, Bradley KA, Campbell CI, Curtis ME, Fiellin D, Ghitza U, Hefner K, Hser YI, McHugh RK, McPherson SM, Mooney LJ, Moran LM, Murphy SM, Schwartz RP, Shmueli-Blumberg D, Shulman M, Stephens KA, Watkins KE, Weiss RD, Wu LT. Karnik NS, et al. Among authors: shmueli blumberg d. Addiction. 2022 Sep;117(9):2438-2447. doi: 10.1111/add.15875. Epub 2022 Apr 25. Addiction. 2022. PMID: 35293064 Free PMC article.
Suicidality as a Predictor of Overdose among Patients with Substance Use Disorders.
Horigian VE, Schmidt RD, Shmueli-Blumberg D, Hefner K, Feinberg J, Kondapaka R, Feaster DJ, Duan R, Gonzalez S, Davis C, Marín-Navarrete R, Tross S. Horigian VE, et al. Among authors: shmueli blumberg d. J Clin Med. 2022 Oct 29;11(21):6400. doi: 10.3390/jcm11216400. J Clin Med. 2022. PMID: 36362628 Free PMC article.
19 results